Determination of mebudipine in human plasma by liquid chromatographyâ��tandem mass spectrometry by Asgari, A. et al.
Original Article
Determination of Mebudipine in Human Plasma by Liquid 
Chromatography–tandem Mass Spectrometry
Arezoo Asgaria, Farzad Kobarfardb, Fariborz Keyhanfarc, Shohreh Mohebbid 
and Maryam Noubarania*
aDepartment of Pharmacology and Toxicology, School of Pharmacy, Zanjan University of 
Medical Sciences, Zanjan, Iran. bDepartment of Medicinal Chemistry, School of Pharmacy, 
Shahid Beheshti University of Medical Sciences, Tehran, Iran. cDepartment of Pharmacology, 
Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. dDepartment of 
Medicinal Chemistry, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, 
Iran.
Abstract
In previous studies, mebudipine, a dihydropyridine calcium channel blocker, showed a 
considerable potential to be used in cardiovascular diseases. The aim of the current study was to 
develop a valid method using reversed-phase high performance liquid chromatography coupled 
with electrospray ionization mass spectrometry to assay mebudipine in the human plasma. 
Separation was achieved on a Zorbax Eclipse® C18
 
analytical column using a mobile phase 
consisted of methanol/water (90:10, v/v). The flow rate was 0.6 mL/min and carbamazepine was 
used as an internal standard (IS). This method involved the use of [M +Na]+ ions of mebudipine 
and IS at m/z 411 and 259, respectively with the selected ion monitoring (SIM) mode. There 
were no interfering peaks from endogenous components in blank plasma chromatograms. 
Standard curves were linear (r2>0.99) between 5 to 100 ng/mL. The mean extraction efficiency 
was about 84% and the limit of quantification for mebudipine was 5 ng/mL in plasma. The 
coefficient of variation and error at all of the intra-day and inter-day assessments were less than 
11%. The results indicated that this method is a fast, accurate, sensitive, selective and reliable 
method for the determination of mebudipine in the human plasma. The assay method has been 
successfully used to estimate plasma concentration of mebudipine after the oral administration 
of 2.5 mg tablet in healthy adults. 
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Introduction
Mebudipine [(±)-t-butyl, methyl-1, 
4-dihydro-2, 6-dimethyl-4 -(3-nitrophenyl)-
3,5-pyridine dicarboxylate] is a dihydropyridine 
derivative with a calcium channel blocking 
property (Figure 1) that was first synthesized 
by Mahmoudian et al. in 1997 (1).
Calcium channel blocking property of 
mebudipine was confirmed in early studies (1,2). 
Also mebudipine antagonizes the contractile 
response of K+-depolarized guinea-pig common 
bile duct to calcium (3). Mebudipine is as potent 
as amlodipine in inhibition of peak Ca2+ currents 
in differentiated PC12 cells (4).
Mebudipine is a vasoselective and potent 
blood pressure lowering compound (5). Due 
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studies of mebudipine in human. The aim of the 
present study was to develop a sensitive, simple, 
fast and reliable LC/ESI-MS method for the 
determination of mebudipine in human plasma.
Experimental
Chemicals
HPLC grade acetonitrile and methanol 
(Darmstadt,Germany) were used for the LC/
MS analysis. Deionized water was used from 
a Milli-Q system (Millipore, Bedford, MA, 
USA). Sodium chloride and acid formic were 
purchased from Merck (Darmstadt, Germany). 
Mebudipine was obtained from the laboratory 
in Iran University of Medical Sciences (Tehran). 
All other chemicals were of analytical grade.
Apparatus and chromatographic conditions
 Liquid chromatography
Separations were performed on a 150 mm 
× 4.6 mm OD, 5 μm particle, Agilent Zorbax 
Eclipse® C18 analytical column. The mobile 
phase was a mixture of methanol/water (90:10, 
v/v) and the pH of the mixture was adjusted 
at 2.6 with formic acid and delivered at a flow 
rate of 0.60 mL/min. Total run time was 7 min. 
The wavelength of UV detection was set at 238 
and 284 for mebudipine and carbamazepine as 
internal standard (IS) assay, respectively.
Mass spectrometry
An agilent LC/MS-6410 Triple Quadruple 
mass spectrometer interfaced with electrospray 
to selective and protective effect in ischemic 
regions (ischemia-selectivity), antioxidant 
activity against myocardial ischemia-reperfusion 
injury (6) reduction in the intensity of myocardial 
ischaemia–reperfusion injury (7) and lack 
of harmful effects such as reflex tachycardia 
and heart failure which have sometimes been 
seen with the older agents (8), mebudipine 
is candidated to be used in cardiovascular 
diseases. Previous studies have demonstrated 
that mebudipine exhibited other effects such as 
inhibition of  phenylephrine-elicited perfusion 
pressure in isolated kidney from diabetic rats 
(9,10) and protective effects against glutamate 
and oxygen–glucose deprivation-induced 
neurotoxicity (11,12). Also it was reported 
that mebudipine and its metabolites are not 
mutagenic on Salmonella TA102 (13).
Mebudipine has potential for further 
development in view of its comparable potency 
to nifedipine but animal models have shown that 
mebudipine›s oral bioavailability is very low, 
which is similar to other dihydropyridins (14-
17). Slow rates of dissolution and extensive first-
pass effects cause the low oral bioavailability of 
these dihydropyridines. In recent study low oral 
bioavailability of mebudipine was improved by 
using phytosolve and phosal-bsed formulation 
(18). A sensitive and specific analytical method 
is needed for determination of mebudipine 
in human after oral administration. Although 
some Gas Chromatogrphy (GC) methods could 
provide high sensitivity for the pharmacokinetic 
study, thermal decomposition of mebudipine 
under GC condition has been the major problem. 
High performance liquid chromatography 
(HPLC) coupled with ultra violet  detection 
offers another possibility for the determination 
of mebudipine in biological samples, but these 
methods were limited by low sensitivity, long 
analysis time or large volume of plasma samples 
required (19).
Liquid chromatography-mass spectrometry 
(LC/MS) is now a routine technique that can be 
applied to a wide range of biological molecules 
and play an important role in several areas of 
clinics (20,21) thus the high sensitivity and fast 
analysis of Liquid Chromatography–tandem 
Mass Spectrometry (LC/MS-MS) may also 
benefit in the pharmacokinetic and clinical 
Figure 1. Chemical structure of mebudipine. 
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ionization (ESI) ion source was used. Positive 
selected ion monitoring (SIM) mode and [M 
+Na]+ for both mebudipine (m/z 388→411) and 
carbamazepine (m/z 236 → 259) were chosen 
for determination of mebudipine (Figure 2). 
Optimal MS parameters were as follows: Drying 
gas (nitrogen) flow rate: 6 L/min, Nebulizing gas 
adjusted at 15 psi, capillary voltage of 4.0 kV, 
and desolvation temperature of 300 ºC. Nitrogen 
was used as the desolvation gas. The data were 
processed using MassHunter software.
Plasma sample preparation
To a 450 µL aliquot of plasma sample in a 2 
mL clean tube, 50 µL of IS solution and 500 µL 
acetonitrile and NaCl were added. The mixture 
was vortexed for 1 min. After centrifugation 
at 8000 rpm for 5 min, the upper layer was 
transferred into an autosampler vial. An aliquot 
of 20 µL was injected into the LC/MS-MS 
system for analysis.
Preparation of standard solutions 
The stock solutions of mebudipine (1 mg/
mL) and IS (carbamazepine 500 ng/mL) were 
prepared in methanol. Working solutions were 
prepared from the stock solution by sequential 
dilution with methanol just before use and were 
protected from light by covering them with 
aluminum foil.
Method validation
The method was validated for selectivity, 
linearity, precision, accuracy, extraction 
recovery, matrix effect and stability according 
to FDA guidance for validation of bioanalytical 
methods (22).
Selectivity
The selectivity was evaluated by comparing 
chromatograms of different batches of blank 
plasma obtained from six subjects with those of 
corresponding standard plasma samples spiked 
with mebudipine and IS, and those of plasma 
samples obtained after oral dose of 2.5 mg 
mebudipine tablet.
Linearity and LLOQ
To 400 μL of blank human plasma, 50 
μL of working standard of mebudipine was 
added, yielding final concentrations of 5-100 
ng/mL of mebudipine. To this mixture, 50 μL 
of IS working solution was added to yield IS 
concentration of 50 ng/mL. Calibration samples 
were prepared for analysis as described above. 
Figure 2. Single Ion Monitoring (SIM) mass spectrum for mebudipine (A) and carbamazepine (B).
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Calibration curve was analyzed three times with 
at least six different concentrations using the 
same LC conditions as described above. The 
peak area ratios of drugs to the IS for each of the 
standard solutions were calculated and plotted 
as a function of drug concentrations in human 
plasma. The calibration curves were acceptable 
only if they had correlation coefficients (r2) of 
0.99 or greater. The acceptance criterion for each 
back-calculated standard concentration was 15% 
deviation from the nominal value except for the 
lower limit of quantification (LLOQ), which 
was set at 20% (22). The LLOQ is defined as the 
lowest concentration on the calibration curve, 
at which an acceptable accuracy (error) within 
±20% and a precision (coefficient of variation, 
CV) below 20% can be obtained.
Precision and accuracy
To examine the accuracy and precision 
of our method, plasma spiked with three 
concentrations consisting of LLOQ, middle and 
high concentrations of the analyte were prepared. 
Intra-day precision and accuracy were evaluated 
by analyzing the spiked controls three times a 
day. This was repeated on three separate days 
to permit an assessment of inter-day accuracy 
and precision. Precision was evaluated at each 
concentration by comparing the values for the 
coefficient of variation: CV % = (SD/ mean 
measured concentration) × 100 and accuracy of 
the assay was determined in terms of % error 
by dividing the measured concentration minus 
the expected concentration to the expected 
concentration × 100.
Extraction recovery 
The extraction efficiency of mebudipine was 
determined by analyzing six replicates of plasma 
samples at three concentration levels of 10, 50 
and 100 ng/mL. The recovery was calculated 
by comparing the peak areas obtained from 
extracted spiked samples with unextracted equal 
amount of standards.
Application to human study
In order to test for utility of the described 
method for determination of mebudipine 
concentration after oral administration, 
mebudipine was administered as a single oral 
dose in male subjects. Two subjects aged 27-50 
years, weighted 54-83 Kg enrolled in the study. 
All the subjects were healthy and none were 
taking any medication. The plasma samples 
were collected up to 6 h after a single oral dose 
of 2.5 mg mebudipine. Blood samples were 
collected in heparinized tubes and centrifuged 
for 15 min at 3000 rpm and the plasma was 
separated and stored at -80 ºC until analysis. 
450 µL plasma sample was spiked with 50 μL 
IS and processed as mentioned in the extraction 
procedure section.
Results and Discussion
Optimization of chromatographic and mass 
spectrometric condition
Chromatographic conditions were optimized 
to obtain high sensitivity, good peak shape and 
short retention time. Composition of the mobile 
phase was found to be the critical factor for 
achieving good chromatographic peak shape 
and resolution. In the present study, a mixture 
of methanol/water (90:10 v/v, pH adjusted at 
2.6) was used as a mobile phase. The selection 
of carbamazepine as the IS was based on 
that several substances, such as nifedipine, 
carbamazepine, phenytoin and amlodipine, 
were tested as IS. Among these, carbamazepine 
has been chosen because of its stability and the 
appropriate elution time. Several extraction 
solvents including diethyl ether, perchloric 
acid, zinc sulphate, tert-butyl methyl ether and 
acetonitril were investigated for the liquid–liquid 
extraction resulting in low recovery or multiple 
step in extraction. Acetonitrile was found to 
be more efficient with extraction recovery of 
mebudipine about 84%, while the recoveries of 
other solvents were below 45%. Furthermore, the 
sample preparation procedure which consists of 
one-step protein precipitation and direct injection 
is much simpler than those of other methods. 
Quality control samples were stable for 1 months 
if stored frozen at below −80 ºC. It was found 
that mebudipine was stable at room temperature 
for 12 h. The standard solutions of mebudipine 
in mobile phase allowed standing at room 
temperature 12 h and prepared freshly every day.
In order to select an appropriate ionization 
mode in LC/MS analysis, the mass spectra were 
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from the analyte of interest are monitored. 
Chromatograms of the blank and the spiked 
human plasma samples (Figure 3) indicated no 
significant interferences at the retention time 
areas of the analyte. ESI positive MS spectra 
for mebudipine and IS were dominated by the 
[M+23]+ ions, i.e. m/z 411 for mebudipine and 
259 for carbamazepine. 
It was very important to investigate the matrix 
effects to develop a reliable and reproducible 
LC/ESI–MS method. Here, the matrix effect 
was evaluated by the following experiments: 
mebudipine and carbamazepine were spiked 
separately into human blank plasma as well as 
into the mobile phase as solvent. After being 
treated according to the procedure described in 
section of sample preparation, these samples 
were injected into LC/ESI-MS. No significant 
difference was observed between the peak area 
in chromatogram of spiked plasma samples and 
the peak area in the chromatogram obtained 
by injection of the solution of mebudipine 
and IS in mobile phase. It was also shown 
acquired in ESI mode by scanning from 50 to 
850 amu. The base peak intensities obtained in 
positive mode were higher than those obtained 
in negative mode. The positive ion mass 
spectra of mebudipine and IS in scan mode 
were characterized by a Na adduct molecular 
ion [M +Na]+ at m/z 411 and 259, respectively 
as base peaks. Therefore, SIM mode involved 
selective monitoring of m/z 411 and 259 in the 
vicinity of retention times for mebudipine and 
carbamazepine, respectively. The optimized 
ESI-MS conditions are described in Mass 
spectrometry section.
A few representative chromatograms of 
mebudipine and carbamazepine are shown 
in Figure 3. The retention times of IS and 
mebudipine in total ion chromatogram were 2.86 
and 3.82 min, respectively.
Method validation
Selectivity
The LC/ESI–MS method shows high 
selectivity because only selected ions 
Figure 3. Representative SIM chromatograms of mebudioine. (A) Blank human plasma; (B) plasma spiked with mebudipine at the 
LLOQ of 5 ng/mL; (C) plasma sample from a volunteer 2.5 h after oral administration of 2.5 mg mebudipine.
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that no endogenous compounds significantly 
influenced the ionization of mebudipine and 
IS. 
Linearity and LLOQ
The standard calibration curves for mebudipine 
were linear over the concentration range of 5 
–100 ng/mL (r2 ≥ 0.99). A typical regression 
equation for the calibration curves was Y=0.02X 
+ 0.036, r2 = 0.997, where Y is the peak area ratio 
of mebudipine to IS, and X is the concentration of 
mebudipine in plasma (Figure 4).
The method reported here is very sensitive 
due to using optimum ESI-MS conditions and 
the advantages of LC/ESI-MS in the selected 
ion monitoring (SIM) mode. The lowest 
standard concentration in the calibration curve 
was considered as the LLOQ, which was 5 ng/
mL. For LLOQ, the mean deviation percentage 
from the nominal concentration was 7.36% 
and precision was 1.3%. A good signal-to-
noise ratio (10:1) was observed at the LLOQ 
indicating that the corresponding value could 
be reached.
Precision and accuracy
The data of intra- and inter-day precision and 
accuracy for mebudipine from quality control 
samples are presented in Table 1. Coefficient of 
variation and error at all of the intra-day and inter-
day assessment were less than 11%. The precision 
and accuracy of the present method conformed to 
the criteria for the analysis of biological samples 
according to the guidance of FDA where the CV 
determined at each concentration level is required 
to be not exceeding 15% (20% for LLOQ) and 
error within ±15% (±20% for LLOQ) of the 
actual value.
Extraction efficacy
Recovery of mebudipine was determined 
by comparing the peak area of the analyte 
extracted from the plasma with peak area 
obtained by the direct injection of pure standard 
analyte in mobile phase at three different 
concentrations containing low, middle and high 
concentration of mebudipin separately. The 
extraction recoveries of mebudipin from human 
plasma were 81.46%, 85.61% and 87.17% 
at concentrations of 10, 50 and 100 ng/mL, 
respectively (Table 2).
Application to human study
The developed method was successfully 
Figure 4. Calibration curve for mebudipine.
Intra-day (n=5) Inter-day (n=3)
Mebudipine (ng/mL) mean ± S.D CV% error% mean ± S.D CV% error%
5 5.12 ± 0.54 10.54 2.4 5.01 ± 0.21 4.19 0.2
50 49.53 ± 4.64 9.37 0.93- 51.93 ± 5.2 10.01 3.86
100 106.02 ± 1.82 1.72 6.02 110.44 ± 9.47 8.57 10.44
Table 1. Precision and accuracy for determination of mebudipine in human plasma (intra-day: n=5; inter-day: n=3 series per day, 3 days).
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Concentration (ng/mL) Mebudipine (%)
10 81.46 ± 6.7
50 85.61 ± 5.8
100 87.17 ± 5.1
Table 2. Recoveries of mebudipine (n=3)
used for determination of plasma concentration 
of mebudipine after oral administration of 
single 2.5 mg tablet to healthy subjects. Mean 
serum concentration–time profiles mebdipine 
is shown in Figure 5. Peak plasma levels of 
mebudipine occurred after 2.5 h. After Cmax was 
reached the plasma drug level declined rapidly 
with t1/2 of 0.6 ± 0.07 h.
Conclusions
In conclusion, we have developed and 
validated a rapid, sensitive and specific LC/
ESI-MS method for determine of mebudipine 
in human plasma. According to our knowledge 
this is the first report on mebudipine detection 
in human plasma. Considering the fact that this 
validated method involves highly specific Mass 
detector it can be said that the current method is 
sensitive and reproducible enough to be used in 
pharmacokinetic studies.
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